The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2).
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck Serono; Takeda
Research Funding - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Toshiaki Watanabe
Consultant or Advisory Role - Bristol-Myers Squibb; Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Masaki Mori
No relevant relationships to disclose
Atsushi Ohtsu
Employment or Leadership Position - Celgene (I)
Tsunekazu Mizushima
No relevant relationships to disclose
Kentaro Yamazaki
Honoraria - Chugai Pharma; Yakult Honsha
Eiji Sunami
No relevant relationships to disclose
Kuniaki Shirao
No relevant relationships to disclose
Atsushi Sato
Honoraria - Chugai Pharma; Yakult Honsha
Research Funding - Chugai Pharma
Satoshi Morita
Honoraria - Chugai Pharma
Takeharu Yamanaka
No relevant relationships to disclose
Axel Grothey
No relevant relationships to disclose
Daniel J. Sargent
No relevant relationships to disclose
Junichi Sakamoto
No relevant relationships to disclose
Shigetoyo Saji
No relevant relationships to disclose